{"transactions":[{"id":932309,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:08.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001686295-26-000002","document":"form4-01232026_040104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000168629526000002/form4-01232026_040104.xml","form_type":"4"}},{"id":1289540,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:36:56.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-25-002493","document":"form4-01312025_090152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002493/form4-01312025_090152.xml","form_type":"4"}},{"id":1289539,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-31T21:36:56.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001415889-25-002493","document":"form4-01312025_090152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002493/form4-01312025_090152.xml","form_type":"4"}},{"id":1640990,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:37:35.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":225000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001415889-24-003967","document":"form4-02152024_100227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003967/form4-02152024_100227.xml","form_type":"4"}},{"id":2013644,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:12:27.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":2.92,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-23-022391","document":"tm236831-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923022391/tm236831-6_4seq1.xml","form_type":"4"}},{"id":2863786,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:46:31.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":398935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest as to 25% on September 17, 2020 and in equal monthly installments thereafter over the following three years."}],"balance_after":398935,"derivative":{"exercise_price":1.74,"expiration_date":"2030-01-21","underlying":"Class A Common Stock","underlying_shares":398935},"source":{"system":"sec-edgar","filing":"0001209191-21-010332","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010332/doc4.xml","form_type":"4"}},{"id":2863785,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:46:31.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":398935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria."}],"balance_after":398935,"derivative":{"exercise_price":4.6,"expiration_date":"2030-10-04","underlying":"Class A Common Stock","underlying_shares":398935},"source":{"system":"sec-edgar","filing":"0001209191-21-010332","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010332/doc4.xml","form_type":"4"}},{"id":3562754,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:16:49.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":110000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":1.31,"underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-023688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119023688/doc4.xml","form_type":"4"}},{"id":3562753,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:16:49.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":113335,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":4.4,"underlying":"Common Stock","underlying_shares":113335},"source":{"system":"sec-edgar","filing":"0001209191-19-023688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119023688/doc4.xml","form_type":"4"}},{"id":3562752,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:16:49.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":110000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":4.05,"underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-023688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119023688/doc4.xml","form_type":"4"}},{"id":3562751,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Restricted Stock Units","published_at":"2019-04-04T17:16:49.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":72620,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested\nautomatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in\nrespect of each share of Issuer common stock underlying such awards."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested\nautomatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in\nrespect of each share of Issuer common stock underlying such awards."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":72620},"source":{"system":"sec-edgar","filing":"0001209191-19-023688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119023688/doc4.xml","form_type":"4"}},{"id":3562750,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2019-04-04T17:16:49.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":6136,"price":5.85,"value":35895.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune\nDesign Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware\ncorporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving\ncorporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to\nreceive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement (\"Merger\nConsideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-023688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119023688/doc4.xml","form_type":"4"}},{"id":3702041,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-07T20:34:44.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date."}],"balance_after":110000,"derivative":{"exercise_price":1.31,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-002669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119002669/doc4.xml","form_type":"4"}},{"id":3702040,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2019-01-07T20:34:44.000Z","date":"2019-01-07","kind":"sale","acquired":false,"shares":3522,"price":1.5717,"value":5535.5274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.5635 to $1.621 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":78756,"source":{"system":"sec-edgar","filing":"0001209191-19-002669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119002669/doc4.xml","form_type":"4"}},{"id":3702039,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2019-01-07T20:34:44.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date."}],"balance_after":82278,"source":{"system":"sec-edgar","filing":"0001209191-19-002669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919119002669/doc4.xml","form_type":"4"}},{"id":3769615,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2018-11-09T16:13:11.000Z","date":"2018-11-07","kind":"grant","acquired":true,"shares":29953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock units shall vest in a single installment on November 7, 2019, subject to the Reporting Person's continuous service through such date."}],"balance_after":57278,"source":{"system":"sec-edgar","filing":"0001209191-18-057941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118057941/doc4.xml","form_type":"4"}},{"id":3864577,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"grant","acquired":true,"shares":19584,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 29,375 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 19,584 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in thirty six (36) equal consecutive monthly installments beginning on August 17, 2018."}],"balance_after":19584,"derivative":{"exercise_price":4.4,"expiration_date":"2025-07-17","underlying":"Common Stock","underlying_shares":19584},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864576,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"disposition_to_issuer","acquired":false,"shares":29375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 29,375 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 19,584 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option provided for 1/4th of the shares underlying the option on January 4, 2018 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":29375},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864575,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"grant","acquired":true,"shares":417,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 625 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 417 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in thirty six (36) equal consecutive monthly installments beginning on August 17, 2018."}],"balance_after":417,"derivative":{"exercise_price":4.4,"expiration_date":"2025-07-17","underlying":"Common Stock","underlying_shares":417},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864574,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"disposition_to_issuer","acquired":false,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 625 shares of the issuer's common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 417 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option provided for 1/4th of the shares underlying the option on January 4, 2018 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864573,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"grant","acquired":true,"shares":58155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,232 shares of the issuer's common stock granted to the reporting person on November 1, 2016. In exchange, the reporting person received a replacement option, for 58,155 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018."}],"balance_after":58155,"derivative":{"exercise_price":4.4,"expiration_date":"2025-07-17","underlying":"Common Stock","underlying_shares":58155},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864572,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"disposition_to_issuer","acquired":false,"shares":87232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,232 shares of the issuer's common stock granted to the reporting person on November 1, 2016. In exchange, the reporting person received a replacement option, for 58,155 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option provided for vesting of 1/4th of the shares underlying the option on October 1, 2017 and the remainder of the shares at a rate of 1/36th per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.58,"expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":87232},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864571,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"grant","acquired":true,"shares":35179,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 52,768 shares of the issuer's common stock granted to the reporting person on October 1, 2016. In exchange, the reporting person received a replacement option, for 35,179 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018."}],"balance_after":35179,"derivative":{"exercise_price":4.4,"expiration_date":"2025-07-17","underlying":"Common Stock","underlying_shares":35179},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":3864570,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (Rt to Buy)","published_at":"2018-07-19T18:01:03.000Z","date":"2018-07-17","kind":"disposition_to_issuer","acquired":false,"shares":52768,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 52,768 shares of the issuer's common stock granted to the reporting person on October 1, 2016. In exchange, the reporting person received a replacement option, for 35,179 shares, having an exercise price of $4.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option provided for vesting of 1/4th of the shares underlying the option on October 1, 2017 and the remainder of the shares at a rate of 1/36th per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.58,"expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":52768},"source":{"system":"sec-edgar","filing":"0001209191-18-043393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118043393/doc4.xml","form_type":"4"}},{"id":4104316,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2018-01-08T20:16:33.000Z","date":"2018-01-05","kind":"sale","acquired":false,"shares":675,"price":4.1725,"value":2816.4375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018."},{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 5, 2018, the reporting person filed a Form 4 that inadvertently reported (i) an incorrect transaction date and (ii) omitted an applicable footnote referring to the fact that the shares were sold pursuant to a current 10b5-1 trading plan."}],"balance_after":27325,"source":{"system":"sec-edgar","filing":"0001209191-18-002807","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118002807/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-05"}},{"id":4105639,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-05T18:30:24.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date."}],"balance_after":110000,"derivative":{"exercise_price":4.05,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-18-002547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118002547/doc4.xml","form_type":"4"}},{"id":4105638,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2018-01-05T18:30:24.000Z","date":"2018-01-04","kind":"sale","acquired":false,"shares":675,"price":4.1725,"value":2816.4375,"ownership":{"direct":true},"balance_after":27325,"source":{"system":"sec-edgar","filing":"0001209191-18-002547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118002547/doc4.xml","form_type":"4"}},{"id":4105637,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2018-01-05T18:30:24.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001209191-18-002547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919118002547/doc4.xml","form_type":"4"}},{"id":4496604,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-06T20:51:42.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One quarter of the shares underlying the option will vest on January 4, 2018, and the remainder of the shares underlying the option will vest at a\nrate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date."}],"balance_after":30000,"derivative":{"exercise_price":5.6,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-002792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919117002792/doc4.xml","form_type":"4"}},{"id":4496603,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Common Stock","published_at":"2017-01-06T20:51:42.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"One quarter of the total restricted stock units vest annually beginning January 4, 2018, subject to the Reporting Person's continuous service through each such date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-17-002792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919117002792/doc4.xml","form_type":"4"}},{"id":4587306,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Clinic. Devel. & CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-10-04T16:35:57.000Z","date":"2016-10-01","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the shares underlying the option will vest on October 1, 2017, and the remainder of the shares underlying the option will vest monthly in equal installments at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date."}],"balance_after":140000,"derivative":{"exercise_price":7.58,"expiration_date":"2026-10-01","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-16-144286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686295/000120919116144286/doc4.xml","form_type":"4"}}]}